At the time of writing, Verona Pharma Plc ADR [VRNA] stock is trading at $104.77, up 20.62%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRNA shares have gain 15.79% over the last week, with a monthly amount glided 24.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on July 01, 2025, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $170. Previously, TD Cowen started tracking the stock with Buy rating on April 28, 2025, and set its price target to $100. On April 21, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $80 on the stock. ROTH MKM started tracking the stock assigning a Buy rating and suggested a price target of $68 on January 10, 2025. Wells Fargo initiated its recommendation with a Overweight and recommended $50 as its price target on October 03, 2024.
For the past year, the stock price of Verona Pharma Plc ADR fluctuated between $16.61 and $99.01. Currently, Wall Street analysts expect the stock to reach $113.6 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $104.77 at the most recent close of the market. An investor can expect a potential return of 8.43% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.16%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.9 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 104.69 points at the first support level, and at 104.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 104.89, and for the 2nd resistance point, it is at 105.01.
Ratios To Look Out For
It is important to note that Verona Pharma Plc ADR [NASDAQ:VRNA] has a current ratio of 8.86. On the other hand, the Quick Ratio is 8.73, and the Cash Ratio is 7.1. Considering the valuation of this stock, the price to sales ratio is 75.23, the price to book ratio is 39.36.
Transactions by insiders
Recent insider trading involved Fisher Andrew, General Counsel, that happened on Jun 16 ’25 when 80000.0 shares were sold. Chief Financial Officer, Hahn Mark W completed a deal on Jun 11 ’25 to sell 0.4 million shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 0.4 million shares on Jun 11 ’25.
